Publications

Oncotarget

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

15-12-2015

Current colorectal cancer reports

Treatment Individualization in Colorectal Cancer.

01-12-2015

Nature medicine

The consensus molecular subtypes of colorectal cancer.

01-11-2015

Breast cancer research : BCR

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

03-10-2015

Molecular oncology

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

01-10-2015

Cell reports

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

29-09-2015

European urology

Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

01-08-2015

Cell research

A price to pay for tumor regression.

01-07-2015

Molecular oncology

Hurdles on the road to personalized medicine.

01-05-2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

20-04-2015

Cell research

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

01-04-2015

International journal of cancer

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

15-03-2015

Oncogene

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

22-01-2015

Cell cycle (Georgetown, Tex.)

Resistance to targeted cancer drugs through hepatocyte growth factor signaling.

27-11-2014

Proceedings of the National Academy of Sciences of the United States of America

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

21-10-2014

Trends in biochemical sciences

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

01-10-2014

Molecular oncology

Drug resistance to targeted therapies: déjà vu all over again.

12-09-2014

Cell reports

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

11-09-2014

Cancer research

USP9X downregulation renders breast cancer cells resistant to tamoxifen.

15-07-2014

Molecular systems biology

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

01-07-2014

Cancer discovery

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

01-05-2014

Oncogene

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.

24-04-2014

Cell reports

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

10-04-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

Cancer discovery

Unlikely suspects identified in neuroblastoma conspiracy.

01-04-2014

Current opinion in genetics & development

Finding effective cancer therapies through loss of function genetic screens.

01-02-2014

Breast cancer research and treatment

Long-term impact of the 70-gene signature on breast cancer outcome.

01-02-2014

Molecular oncology

A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.

01-10-2013

Cell cycle (Georgetown, Tex.)

TGF-β: an emerging player in drug resistance.

15-09-2013

Breast cancer research and treatment

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.

01-08-2013

Molecular and cellular biology

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

01-08-2013

The Journal of pathology

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

01-07-2013

The Journal of pathology

An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.

01-03-2013

Cell

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

21-11-2012

Cell

A missing link in genotype-directed cancer therapy.

26-10-2012

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Understanding resistance to targeted cancer drugs through loss of function genetic screens.

01-10-2012

Bioinformatics (Oxford, England)

A regression model for estimating DNA copy number applied to capture sequencing data.

15-09-2012

Journal of cellular and molecular medicine

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

01-09-2012

Oncogene

Targeting the epigenome for treatment of cancer.

23-08-2012

Breast cancer research and treatment

Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.

01-02-2012

Nature

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

26-01-2012

PloS one

The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence.

08-10-2011

Cancer discovery

Functional subtyping of breast cancer.

01-08-2011

Nature medicine

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

01-03-2011

Nature cell biology

TSPYL5 suppresses p53 levels and function by physical interaction with USP7.

01-01-2011

Cancer research

Twenty-second annual Pezcoller Symposium: RNA biology and cancer.

15-12-2010

Cell

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

23-07-2010

Clinical cancer research : an official journal of the American Association for Cancer Research

Inhibition of the PI3K pathway: hope we can believe in?

15-06-2010

Molecular cancer research : MCR

The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling.

01-06-2010

Cell

It's diagnostics, stupid.

02-04-2010

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

Treatment Individualization in Colorectal Cancer.

The consensus molecular subtypes of colorectal cancer.

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

A price to pay for tumor regression.

Hurdles on the road to personalized medicine.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

Resistance to targeted cancer drugs through hepatocyte growth factor signaling.

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

Drug resistance to targeted therapies: déjà vu all over again.

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

USP9X downregulation renders breast cancer cells resistant to tamoxifen.

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Unlikely suspects identified in neuroblastoma conspiracy.

Finding effective cancer therapies through loss of function genetic screens.

Long-term impact of the 70-gene signature on breast cancer outcome.

A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.

TGF-β: an emerging player in drug resistance.

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

A missing link in genotype-directed cancer therapy.

Understanding resistance to targeted cancer drugs through loss of function genetic screens.

A regression model for estimating DNA copy number applied to capture sequencing data.

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

Targeting the epigenome for treatment of cancer.

Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence.

Functional subtyping of breast cancer.

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

TSPYL5 suppresses p53 levels and function by physical interaction with USP7.

Twenty-second annual Pezcoller Symposium: RNA biology and cancer.

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Inhibition of the PI3K pathway: hope we can believe in?

The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling.

It's diagnostics, stupid.

This site uses cookies